Conivaptan Systematic (IUPAC) name N-(4-(4,5-dihydro-2-methylimidazo[4,5-d]benzazepin- 6(1H)-yl)carbonyl)phenyl)- (1,1'-biphenyl)-2-carboxamide Clinical data AHFS/Drugs.com Pregnancy cat. ? Legal status ? Routes intravenous Pharmacokinetic data Bioavailability N/A Identifiers CAS number ATC code C03  PubChem DrugBank ChemSpider UNII KEGG ChEBI ChEMBL Chemical data Formula C32H26N4O2 Mol. mass 498.583 SMILES & (what is this?)
Conivaptan (YM 087, brand name Vaprisol) is a non-peptide inhibitor of antidiuretic hormone (vasopressin receptor antagonist). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH), and there is some evidence it may be effective in heart failure. It is marketed by Astellas Pharma Inc.
Conivaptan has not been approved by the FDA for the treatment of decompensated congestive heart failure. However, in theory, vasopressin receptor antagonism would be particularly useful in this setting, and an initial study shows that it has some promise.
- ^ WHO International Working Group for Drug Statistics Methodology (August 27, 2008). "ATC/DDD Classification (FINAL): New ATC 5th level codes". WHO Collaborating Centre for Drug Statistics Methodology. Archived from the original on 2008-05-06. http://web.archive.org/web/20080506023243/http://www.whocc.no/atcddd/new_atc_ddd.html#ATCDDD_FINAL. Retrieved 2008-09-05.
- ^ Udelson JE, Smith WB, Hendrix GH, et al. (November 2001). "Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure". Circulation 104 (20): 2417–23. doi:10.1161/hc4501.099313. PMID 11705818. http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=11705818.
Antihypertensives: diuretics (C03) Sulfonamides
(except EA)CA inhibitors (at PT)Thiazide-likes (primarily DCT)
Potassium-sparing (at CD)ESC blockers Osmotic diuretics (PT, DL) VAs (DCT and CD) Other #WHO-EM. ‡Withdrawn from market. Clinical trials: †Phase III. §Never to phase III Hypothalamic-pituitary hormones and analogues (H01) Hypothalamic Anterior pituitaryAgonists: Thyrotropin Posterior pituitary Neuropeptidergics Cholecystokinin CRHAgonists: Corticotropin releasing hormone GalaninAgonists: Galanin • Galanin-like peptide • Galmic • GalnonAgonists: Galanin • Galanin-like peptide • Galmic • GalnonAgonists: Galanin • Galmic • Galnon Ghrelin MCHAgonists: Melanin concentrating hormone MelanocortinAgonists: alpha-MSH • Melanotan II Neuropeptide SAgonists: Neuropeptide S
Neuropeptide Y Neurotensin Opioidsee Template:Opioids Orexin Oxytocin TachykininAgonists: Substance P
Antagonists: Aprepitant • Befetupitant • Casopitant • CI-1021 • CP-96,345 • CP-99,994 • CP-122,721 • Dapitant • Ezlopitant • FK-888 • Fosaprepitant • GR-203,040 • GW-597,599 • HSP-117 • L-733,060 • L-741,671 • L-743,310 • L-758,298 • Lanepitant • LY-306,740 • Maropitant • Netupitant • NKP-608 • Nolpitantium • Orvepitant • RP-67,580 • SDZ NKT 343 • Vestipitant • Vofopitant
Vasopressin This hormonal preparation article is a stub. You can help Wikipedia by expanding it. This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.